



Application of Phage Therapy in Antibiotic-Resistant Bacterial Infections

Guest Editors:

Dr. Jason Clark

FixedPhage Ltd., Glasgow G20
0SP, UK

Dr. Jean-Paul Pirnay

Laboratory for Molecular and
Cellular Technology, Queen
Astrid Military Hospital, 1120
Brussels, Belgium

Deadline for manuscript
submissions:

closed (28 February 2023)

Message from the Guest Editors

The rise in antimicrobial resistance (AMR), combined with a dwindling pipeline of new antimicrobials has led to an increasing drive to find ways to supplement our current and future antimicrobial arsenal. The recent interest in phages has been driven by several factors, for example, phages can be used alone or in combination with other antibiotics to treat resistant infections; phages can effectively degrade biofilms; and phages are less disruptive to healthy microbiomes.

This special issue is collating primary research and review papers on the use of phages as alternatives/adjuncts to antibiotics, and in applications where phages could reduce antibiotic use. There is a specific focus on areas affecting the application of phages as therapeutics:

- i) The use of phages in combination with antibiotics and synergism between the two.
- ii) The development and use of phages in “compassionate use” cases in humans/animals.
- iii) The application of phages to biofilms.
- iv) The use of phages to specifically remove unwanted bacteria, while leaving the beneficial commensals intact.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi